Company / Shareholders' Equity
TherapeuticsMD, Inc. Shareholders' Equity History
FY2015-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$29.3M
FY2024
5-year range
-$124.0M / $97.5M
FY2020-FY2024
Trend
-16.7%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Shareholders' Equity has fluctuated over the past 10 years, ranging from -$124M in FY2021 to $130M in FY2019.
Based on SEC 10-K filings.
$29M in FY2024 with a 5-year CAGR of -25.8%.
Improved from -$94M to $29M over the past 2 years.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -25.8%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -25.8%, indicating a declining trend.
- In FY2024, shareholders' equity decreased 16.7% year-over-year.
- Peak shareholders' equity was recorded in FY2019.
- Lowest shareholders' equity in the period was in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 0.77 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $29.3M | -16.7% |
| FY2023 | $35.1M | +137.5% |
| FY2022 | -$93.6M | +24.5% |
| FY2021 | -$124.0M | -227.1% |
| FY2020 | $97.5M | -24.9% |
| FY2019 | $129.9M | +1.9% |
| FY2018 | $127.5M | +102.2% |
| FY2017 | $63.1M | +30.3% |
| FY2016 | $48.4M | -11.5% |
| FY2015 | $54.7M | +3916.7% |
As of FY2024 · SEC 10-K · Updated Jun 28, 2026